ArticleCureus2026
First-Line Enfortumab Vedotin Plus Pembrolizumab in Platinum-Ineligible Urothelial Carcinoma: A Three-Case Series.
Daisuke Igarashi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
2026
this papercites it